Expedia Group, Inc.
$36.24B- Market cap
- $34.12B
- Debt
- +$7.85B
- Cash
- −$5.73B
Capital structure 81% equity / 19% debt · EV / Revenue 2.46x · EV / EBITDA 10.56x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: EXPE stock price vs ZNTL: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ZNTL's multiple
Needs ZNTL P/E.
Implied fair value · at EXPE's multiple
Needs EPS (TTM) is negative, EXPE P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: EXPE FY 2025 (ended Dec 31, 2025) · ZNTL FY 2024 (ended Dec 31, 2024). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 81% equity / 19% debt · EV / Revenue 2.46x · EV / EBITDA 10.56x
Capital structure 78% equity / 22% debt · EV / Revenue 4.96x
EXPE carries the larger enterprise value at $36.24B against $334.64M; EXPE trades on the lower EV / Revenue multiple (2.46x vs 4.96x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
EXPEDIA GROUP, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Zentalis Pharmaceuticals, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
6.12x
0.24x
Net debt / EBITDA
Leverage against operating earnings
0.62x
-0.29x
Cash and equivalents
Liquid reserves on the balance sheet
$5.73B
$33.90M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Booking Holdings Inc.
EXPE vs BKNG
Airbnb, Inc.
EXPE vs ABNB
Delta Air Lines, Inc.
EXPE vs DAL
United Airlines Holdings, Inc.
EXPE vs UAL
Arcus Biosciences, Inc.
EXPE vs RCUS
Repare Therapeutics Inc.
EXPE vs RPTX
IDEAYA Biosciences, Inc.
EXPE vs IDYA
Mersana Therapeutics, Inc.
EXPE vs MRSN
EXELIXIS, INC.
EXPE vs EXEL
$7.85B
$82.57M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.